Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

Lp(a): When to Measure it and What to Do About it

Canadian Collaborative Research Network

M. O'Donoghue

Updated Lipid Guidelines and Therapy

Complex Coronary Cases

I. Fergus

Recent Cholesterol Guidelines and Integration into Clinical Practice

The North American Thrombosis Forum (NATF)

J. Plutzky, L. Braun, J. Ross

AHA 2022: Cardiovascular Benefit of Lowering LDL Cholesterol Below 4…

AHA 2022 Conference Coverage

N. Marston

Lipids Update: Current Guidelines for Lipid Management

Scripps Health

S. R. Mehta

ACC 2023: Management of Statin Side Effects and How to Keep Them on …

ACC 2023 Conference Coverage

J. Saseen

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients Wi…

AHA 2022 Conference Coverage

K. Ray

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

How Do I Reverse Coronary Plaque?

Scripps Health

C. J. Suhar

ACC 2022: Updates on Lowering LDL-C in Secondary Prevention - "Go as…

ACC 2022 Conference Coverage

R. Giugliano

Lipid Lowering Therapies: Where Did We Start, Where We Are Now and W…

The Texas Heart Institute

S. Virani

I Ordered an Lp(a) Level – Now What?

Canadian Collaborative Research Network

M. O'Donoghue

VICTORION-INITIATE – Comparing Inclisiran First to Usual Care in Pat…

Canadian Collaborative Research Network

M. Gupta

Update on Lipids: Current Options for Lowering LDL to Reduce CV Risk

Jefferson Health

A. Cohen

Big Questions About Lipoprotein “Little” (a)

MUSC Cardiology

A. Arana Waring

How to Reduce Cholesterol and Triglycerides to Prevent CV Events

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

P. Taub

ACC 2024 Insights: Measure Lp(a) in All Patients Once: One & Done!

ACC 2024 Insights

S. Mora

Update on Lipoprotein A: The Horrible Cholesterol

Norman Lepor

Do Statins Prevent or Cause Heart Disease? Should LDL Be Called "Bad…

Nadir Ali